BioSpace is delighted to present its NextGen Bio “Class of 2015.” This list contains 30 life science companies that were launched no earlier than in 2011 and are headquartered in the United States. Once the companies were sorted into that group, they were then weighted by a number of different categories and ranked in a cumulative fashion based on the points awarded each category. Those categories are: Finance, Collaborations, Pipeline, Sales and Editorial (view methodology).
The NextGen Bio Class of 2015 is filled with a stellar group of companies that are making enormous impact on the industry now and in the future. Congratulations!
“This recognition is testament to how hard we are working to bring transformative cancer therapies to market. Being named the most promising biopharma startup speaks to the milestones we have achieved in less than a year, including two funding rounds and significant progress in clinical development. It has been an exciting year, but we are even more excited about the progress still to come,” Hans Bishop, chief executive officer of Juno Therapeutics, Inc., told BioSpace.
Location: San Francisco, Calif.
In October 2013, Alector closed on Series A financing led by Polaris Venture Partners and OrbiMed Advisors for an undisclosed amount.
In March 2014, Janssen Pharmaceuticals, the pharmaceutical arm of Johnson & Johnson, agreed to help fund Alector’s efforts to develop new therapies for Alzheimer’s. No financial terms were disclosed.